Skip to main content
. 2021 Dec 15;11(12):6107–6118.

Table 2.

Tumor response in patients with advanced HCC between the two groups (after propensity score matching)

Response Category DEB-TACE+LEN (N=50) (%) DEB-TACE+SOR (N=100) (%) P value
CR 14 (28.0%) 15 (15.0%) 0.057
PR 18 (36.0%) 26 (26.0%) 0.205
ORR (CR+PR) 32 (64.0%) 41 (41.0%) 0.008
DCR (CR+PR+SD) 38 (76.0%) 68 (68.0%) 0.310